Provided by Tiger Trade Technology Pte. Ltd.

Camp4 Therapeutics Corp.

3.70
-0.1400-3.65%
Volume:278.33K
Turnover:1.02M
Market Cap:232.19M
PE:-1.66
High:3.80
Open:3.80
Low:3.51
Close:3.84
52wk High:7.75
52wk Low:2.86
Shares:62.75M
Float Shares:50.71M
Volume Ratio:0.45
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2250
EPS(LYR):-2.6500
ROE:-545.85%
ROA:-45.25%
PB:-335.05
PE(LYR):-1.40

Loading ...

Mar 30, 2023

Correspondence

CORRESP [Cover] - Correspondence
Mar 27, 2023

Major Issues Report

8-K - Current report
Feb 15, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 26, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 20, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Dec 20, 2022

Major Issues Report

8-K - Current report
Dec 02, 2022

Major Issues Report

8-K - Current report
Nov 14, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Oct 18, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Sep 22, 2022

Major Issues Report

8-K - Current report
Sep 22, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 26, 2022

Major Issues Report

8-K - Current report
Aug 23, 2022

Major Issues Report

8-K - Current report
Aug 01, 2022

Major Issues Report

8-K - Current report
Jul 22, 2022

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Jul 15, 2022

Major Issues Report

8-K - Current report
Jun 23, 2022

Major Issues Report

8-K - Current report
Jun 23, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]